NO20092633L - Ernaeringstilskuddsammensetning for behandling av okulare sykdommer - Google Patents

Ernaeringstilskuddsammensetning for behandling av okulare sykdommer

Info

Publication number
NO20092633L
NO20092633L NO20092633A NO20092633A NO20092633L NO 20092633 L NO20092633 L NO 20092633L NO 20092633 A NO20092633 A NO 20092633A NO 20092633 A NO20092633 A NO 20092633A NO 20092633 L NO20092633 L NO 20092633L
Authority
NO
Norway
Prior art keywords
supplement composition
treatment
nutritional supplement
ocular diseases
spot degeneration
Prior art date
Application number
NO20092633A
Other languages
English (en)
Norwegian (no)
Inventor
Georg Ludwig Kis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092633(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20092633L publication Critical patent/NO20092633L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/30Copper compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/315Zinc compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/34Copper; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20092633A 2006-12-15 2009-07-10 Ernaeringstilskuddsammensetning for behandling av okulare sykdommer NO20092633L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06126261A EP1932521A1 (en) 2006-12-15 2006-12-15 Nutritional supplement composition for treatment of ocular diseases
PCT/EP2007/063908 WO2008071775A1 (en) 2006-12-15 2007-12-13 Nutritional supplement composition for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
NO20092633L true NO20092633L (no) 2009-07-10

Family

ID=38024441

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092633A NO20092633L (no) 2006-12-15 2009-07-10 Ernaeringstilskuddsammensetning for behandling av okulare sykdommer

Country Status (22)

Country Link
US (1) US20100028459A1 (ko)
EP (2) EP1932521A1 (ko)
JP (1) JP2010513248A (ko)
KR (1) KR20090089473A (ko)
CN (1) CN101557807A (ko)
AR (1) AR064332A1 (ko)
AU (1) AU2007331432A1 (ko)
BR (1) BRPI0720046A2 (ko)
CA (1) CA2672013A1 (ko)
CL (1) CL2007003630A1 (ko)
CO (1) CO6220929A2 (ko)
EC (1) ECSP099516A (ko)
GT (1) GT200900161A (ko)
MA (1) MA30994B1 (ko)
MX (1) MX2009006306A (ko)
NO (1) NO20092633L (ko)
PE (1) PE20081580A1 (ko)
RU (1) RU2009126735A (ko)
TN (1) TN2009000241A1 (ko)
TW (1) TW200843725A (ko)
WO (1) WO2008071775A1 (ko)
ZA (1) ZA200903862B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389504B2 (en) * 2008-05-08 2013-03-05 Mead Johnson Nutrition Company Prenatal dietary supplement
WO2010074940A1 (en) * 2008-12-23 2010-07-01 Alcon Research, Ltd. Compositions and nutritional supplements for improving ocular health and reducing ocular inflammatory response
US20110237548A1 (en) * 2009-07-23 2011-09-29 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US20130011469A1 (en) 2009-07-23 2013-01-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Krill oil and carotenoid composition, associated method and delivery system
AU2012280056B2 (en) * 2011-07-07 2017-01-12 Maravilla Llc Improvements in or relating to visual performance and/or macular pigmentation
US9381183B2 (en) 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US9115078B2 (en) 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
WO2013037794A1 (en) * 2011-09-12 2013-03-21 Georgiou Tassos Use of omega fatty acids for treating disease
CN102538980A (zh) * 2012-01-12 2012-07-04 杭州美盛红外光电技术有限公司 热像装置和热像拍摄方法
JP2016185939A (ja) * 2015-03-27 2016-10-27 ロート製薬株式会社 経口組成物
JP2016190829A (ja) * 2015-03-31 2016-11-10 ウィルファーム株式会社 活性型dhaを含む製剤、強化食品、サプリメント並びに化粧品
JP6056114B2 (ja) * 2015-05-30 2017-01-11 富田製薬株式会社 油状物質含有粉末組成物
CN108208804A (zh) * 2018-01-05 2018-06-29 美博迪尔(北京)生物科技有限公司 一种缓解眼睛干涩、抵御蓝光损伤及保护眼底的组合物及其制备方法
CN108096288A (zh) * 2018-01-16 2018-06-01 南京圣诺生物科技实业有限公司 护眼片及其制备方法和应用
AU2021235553A1 (en) * 2020-03-11 2022-09-22 Bausch + Lomb Ireland Limited Compositions and methods for eye health comprising very long chain fatty acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002320251A1 (en) * 2001-07-05 2003-01-21 Vital Basics, Inc. Compositions for improving mental performance
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
WO2005027950A1 (en) * 2003-09-12 2005-03-31 Ray And Terry's Health Products, Inc. Eye nutritional supplement
US7887847B2 (en) * 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
DE202005012984U1 (de) * 2005-08-17 2005-11-24 W & B Pharmamarken Gmbh Arzneimittel- und Nahrungsergänzungsmittelkombinationen zur Behandlung von Augenerkrankungen
CN101330840A (zh) * 2005-12-20 2008-12-24 爱尔康研究有限公司 用于抑制黄斑变性进展和促进健康视觉的组合物和方法

Also Published As

Publication number Publication date
BRPI0720046A2 (pt) 2013-12-24
CO6220929A2 (es) 2010-11-19
CA2672013A1 (en) 2008-06-19
EP1932521A1 (en) 2008-06-18
TW200843725A (en) 2008-11-16
GT200900161A (es) 2009-11-30
MA30994B1 (fr) 2009-12-01
PE20081580A1 (es) 2009-01-01
CN101557807A (zh) 2009-10-14
AU2007331432A1 (en) 2008-06-19
TN2009000241A1 (en) 2010-10-18
JP2010513248A (ja) 2010-04-30
RU2009126735A (ru) 2011-01-20
ZA200903862B (en) 2010-05-26
KR20090089473A (ko) 2009-08-21
ECSP099516A (es) 2009-08-28
MX2009006306A (es) 2009-06-23
US20100028459A1 (en) 2010-02-04
EP2094252A1 (en) 2009-09-02
AR064332A1 (es) 2009-04-01
CL2007003630A1 (es) 2008-08-08
WO2008071775A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
NO20092633L (no) Ernaeringstilskuddsammensetning for behandling av okulare sykdommer
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2008002571A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
WO2008002570A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
BRPI0507593A (pt) composições contendo cis-isÈmeros de um composto carotenóide e processo
WO2010043415A3 (en) Whey protein compositions, methods and uses
WO2007081729A3 (en) Treatment modalities for autoimmune diseases
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2010130830A3 (en) Anti-sclerostin vhh and their use for treating bone diseases
WO2007092622A3 (en) Compositions and methods for treating bone
EA200801679A1 (ru) Композиции и способы применения антител к dickkopf-1 и/или -4
WO2007114945A3 (en) Compositions and methods for enhancing the antioxidant status of animals
IL195030A (en) IV dpp inhibitor assemblies
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2010062863A3 (en) Compositions containing satiogens and methods of use
WO2009047644A3 (en) Method of treating vitamin d insufficiency and deficiency
WO2007146425A3 (en) Compounds and methods for treatment of chemotherapy-induced anemia
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
TW200714277A (en) Methods and compositions for altering cell fuction
WO2009085969A3 (en) Compositions and methods to promote implantation and engrafment of stem cells
JO3358B1 (ar) معالجات حساسية العيون
MX2009006342A (es) Composicion de complemento alimenticio para tratamiento de enfermedades oculares.
WO2009004629A3 (en) A method for decreasing symptoms of alcohol consumption
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application